Results 181 to 190 of about 3,321,094 (294)

Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer. [PDF]

iScience
Zhu L, Jia X, Xu L, Chen L, Fu X, Yan H, Ai B, Peng S.   +7 more
europepmc   +1 more source

Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells

FEBS Open Bio, EarlyView.
Type I interferons differentially modulate autophagy and the response of pancreatic cancer cells to gemcitabine. IFNα2b stimulates autophagic flux and protects cells from gemcitabine‐induced cell death, contributing to chemoresistance. In contrast, IFNβ1a inhibits autophagosome formation and enhances gemcitabine‐induced cell death, resulting in ...
Lucy E. Bonilla, Martín M. Ledesma, Santiago A. Behr, Matías A. Pibuel, María L. Palanek, Daniel H. Grasso, Maria N. Garcia, Juan Garona, Silvina L. Lompardía, Elida Álvarez, Daniela L. Papademetrio   +10 more
wiley   +1 more source

Selective elimination of quiescent cancer cells by dequalinium chloride via ROS‐mediated ferroptosis

FEBS Open Bio, EarlyView.
Dequalinium chloride (DQ) selectively eliminates quiescent cancer cells (QCCs) by amplifying mitochondrial ROS. QCCs exhibit elevated basal ROS and limited redox‐buffering capacity, making them vulnerable to further ROS increases. DQ‐induced ROS exceeds the tolerance threshold, triggering lipid peroxidation and ferroptosis, whereas proliferating cells ...
Kotaro Miyamoto, Shiori Sakai, Minori Endo, Terigele, Mizuho Niibori, Taiki Morita, Yu Goto, Arisa Yoshida, Tomohiro Tanaka, Ning Lin, Takahiro Kuchimaru, Hiroyuki Nakamura, Masahiro Inoue, Shinae Kizaka‐Kondoh, Tetsuya Kadonosono   +14 more
wiley   +1 more source

A Bioinformatics and Wet-Lab-Based Pipeline Identifies <i>CLDN10</i> and <i>GJB2</i> as Epigenetically Silenced Tumor Suppressor Genes in Cutaneous Melanoma. [PDF]

Int J Mol Sci
Arroyo Villora S, Baumann VX, Zhao Y, Philipp N, Dammann RH, Sigges C, Richter AM.   +6 more
europepmc   +1 more source

Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma. [PDF]

Clin Epigenetics, 2023
Sgro A, Cursons J, Waryah C, Woodward EA, Foroutan M, Lyu R, Yeoh GCT, Leedman PJ, Blancafort P.   +8 more
europepmc   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

An enteropathogenic microbial toxin modulates the breast cancer epigenome resulting in concurrent silencing of tumor suppressor genes. [PDF]

Breast Cancer Res
Verma D, Nandi D, Parida S, Saxena A, Sharma D.   +4 more
europepmc   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Concurrent mutations in multiple tumor suppressor genes correlate with adverse prognosis in stage I lung adenocarcinoma patients. [PDF]

J Thorac Dis
Wang Y, Xu R, Ren J, Li Y, Chen Y, Zhang L, Qiu Z.   +6 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source